Browsing Category
Pharma Industry News
4730 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Roche’s breast cancer pill inavolisib approved by MHRA for metastatic disease
MHRA approves inavolisib for advanced HR-positive breast cancer. Find out how Roche’s targeted therapy expands treatment options for UK patients.
Mural Oncology shareholders to receive fixed $2.035 per share as XOMA Royalty deal nears closing
Mural Oncology confirms a fixed $2.035 per share cash payout as its acquisition by XOMA Royalty nears closing, locking in a definitive exit for investors.
Galmed Pharmaceuticals (Nasdaq: GLMD) reports Q3 loss but refocuses on oncology with new Aramchol data and once-daily formulation
Galmed Pharmaceuticals shifts focus to oncology after reporting Q3 loss; Aramchol Meglumine’s new formulation shows promise for 2026 Phase 2 trials.
InhaleRx (ASX: IRX) unveils oral esketamine therapy for depression but stock sinks 22% amid investor caution
InhaleRx launches SRX-25 oral esketamine therapy for depression, plans rebrand and raises capital despite 22% stock plunge. Learn what this could mean for investors.
Next-gen RNA therapy SIL204 passes key safety milestone as Silexion Therapeutics prepares Phase 2/3 pancreatic cancer study
Find out how Silexion Therapeutics is advancing SIL204 after a key safety milestone in pancreatic cancer research.
Investors eye PHIO as Phio Pharmaceuticals reports full Phase 1b enrollment and strong preliminary PH-762 results
Find out how Phio Pharmaceuticals’ PH-762 trial progress and early response signals could reshape RNA-based cancer therapies.
PharmaCyte Biotech turns Femasys investment into cash windfall, fueling new strategic opportunities
Find out how PharmaCyte Biotech’s monetized Femasys stake strengthens liquidity and fuels new strategic opportunities.
Is Eli Lilly the NVIDIA of healthcare? How metabolic drugs became the new AI trade
Discover how Eli Lilly and Company crossed the $1 trillion valuation mark and why its metabolic-health franchise is now being valued like a high-growth tech platform—read more now.
Can pharma M&A survive Australia’s new national interest doctrine?
Australia’s FIRB blocked Cosette’s $430M takeover of Mayne Pharma. Can foreign pharma buyers still close deals in this new national interest era?
AstraZeneca (LSE: AZN) goes big on U.S. supply chain with latest $2bn manufacturing push
AstraZeneca invests $2B in Maryland to expand biologics and rare disease drug manufacturing. Find out what this means for U.S. jobs and the pharma supply chain.